Potential of gene therapy for treating osteogenesis imperfecta

C. Niyibizi, P. Smith, Z. Mi, P. Robbins, C. Evans

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Osteogenesis imperfecta is a heterogeneous group of genetic disorders that affect connective tissue integrity, with bone fragility being the major clinical feature. Most forms of osteogenesis imperfecta are the result of mutations in the genes that encode the protα1 and proα2 polypeptide chains of Type I collagen. Because osteogenesis imperfecta is an incurable genetic disease, cell therapy and gene therapy are being investigated as potential treatments. Gene therapy for osteogenesis imperfecta however is a major challenge; because most of the mutations in osteogenesis imperfecta are dominant negative, supplying the normal gene without silencing the abnormal gene may not be beneficial. Null mutations in which an allele is not expressed or absent may be amenable to gene therapy or alternatively after silencing a mutant allele, a normal gene could be supplied. In addition, overexpression of the normal collagen gene in cells expressing mutant collagen polypeptide chains potentially could lead to synthesis of a sufficient percentage of normal molecules to normalize clinical status. The authors currently are examining the possibility of developing gene therapy for treating a mouse model of human osteogenesis imperfecta (oim) using bone marrow stromal cells as vehicles for delivering normal collagen genes to bone. In the current study, the potential of gene therapy for treating osteogenesis imperfecta is discussed in the context of the complexity of the mutations in Type I collagen genes that lead to different osteogenesis imperfecta phenotypes.

Original languageEnglish (US)
Pages (from-to)S126-S133
JournalClinical orthopaedics and related research
Issue number379 SUPPL.
DOIs
StatePublished - Jan 1 2000

Fingerprint

Osteogenesis Imperfecta
Genetic Therapy
Genes
Mutation
Inborn Genetic Diseases
Collagen
Collagen Type I
Alleles
Bone and Bones
Peptides
Gene Silencing
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Connective Tissue
Phenotype

All Science Journal Classification (ASJC) codes

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Niyibizi, C. ; Smith, P. ; Mi, Z. ; Robbins, P. ; Evans, C. / Potential of gene therapy for treating osteogenesis imperfecta. In: Clinical orthopaedics and related research. 2000 ; No. 379 SUPPL. pp. S126-S133.
@article{fc9a03a6263b441eb422e36a7740f3df,
title = "Potential of gene therapy for treating osteogenesis imperfecta",
abstract = "Osteogenesis imperfecta is a heterogeneous group of genetic disorders that affect connective tissue integrity, with bone fragility being the major clinical feature. Most forms of osteogenesis imperfecta are the result of mutations in the genes that encode the protα1 and proα2 polypeptide chains of Type I collagen. Because osteogenesis imperfecta is an incurable genetic disease, cell therapy and gene therapy are being investigated as potential treatments. Gene therapy for osteogenesis imperfecta however is a major challenge; because most of the mutations in osteogenesis imperfecta are dominant negative, supplying the normal gene without silencing the abnormal gene may not be beneficial. Null mutations in which an allele is not expressed or absent may be amenable to gene therapy or alternatively after silencing a mutant allele, a normal gene could be supplied. In addition, overexpression of the normal collagen gene in cells expressing mutant collagen polypeptide chains potentially could lead to synthesis of a sufficient percentage of normal molecules to normalize clinical status. The authors currently are examining the possibility of developing gene therapy for treating a mouse model of human osteogenesis imperfecta (oim) using bone marrow stromal cells as vehicles for delivering normal collagen genes to bone. In the current study, the potential of gene therapy for treating osteogenesis imperfecta is discussed in the context of the complexity of the mutations in Type I collagen genes that lead to different osteogenesis imperfecta phenotypes.",
author = "C. Niyibizi and P. Smith and Z. Mi and P. Robbins and C. Evans",
year = "2000",
month = "1",
day = "1",
doi = "10.1097/00003086-200010001-00017",
language = "English (US)",
pages = "S126--S133",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "379 SUPPL.",

}

Potential of gene therapy for treating osteogenesis imperfecta. / Niyibizi, C.; Smith, P.; Mi, Z.; Robbins, P.; Evans, C.

In: Clinical orthopaedics and related research, No. 379 SUPPL., 01.01.2000, p. S126-S133.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potential of gene therapy for treating osteogenesis imperfecta

AU - Niyibizi, C.

AU - Smith, P.

AU - Mi, Z.

AU - Robbins, P.

AU - Evans, C.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Osteogenesis imperfecta is a heterogeneous group of genetic disorders that affect connective tissue integrity, with bone fragility being the major clinical feature. Most forms of osteogenesis imperfecta are the result of mutations in the genes that encode the protα1 and proα2 polypeptide chains of Type I collagen. Because osteogenesis imperfecta is an incurable genetic disease, cell therapy and gene therapy are being investigated as potential treatments. Gene therapy for osteogenesis imperfecta however is a major challenge; because most of the mutations in osteogenesis imperfecta are dominant negative, supplying the normal gene without silencing the abnormal gene may not be beneficial. Null mutations in which an allele is not expressed or absent may be amenable to gene therapy or alternatively after silencing a mutant allele, a normal gene could be supplied. In addition, overexpression of the normal collagen gene in cells expressing mutant collagen polypeptide chains potentially could lead to synthesis of a sufficient percentage of normal molecules to normalize clinical status. The authors currently are examining the possibility of developing gene therapy for treating a mouse model of human osteogenesis imperfecta (oim) using bone marrow stromal cells as vehicles for delivering normal collagen genes to bone. In the current study, the potential of gene therapy for treating osteogenesis imperfecta is discussed in the context of the complexity of the mutations in Type I collagen genes that lead to different osteogenesis imperfecta phenotypes.

AB - Osteogenesis imperfecta is a heterogeneous group of genetic disorders that affect connective tissue integrity, with bone fragility being the major clinical feature. Most forms of osteogenesis imperfecta are the result of mutations in the genes that encode the protα1 and proα2 polypeptide chains of Type I collagen. Because osteogenesis imperfecta is an incurable genetic disease, cell therapy and gene therapy are being investigated as potential treatments. Gene therapy for osteogenesis imperfecta however is a major challenge; because most of the mutations in osteogenesis imperfecta are dominant negative, supplying the normal gene without silencing the abnormal gene may not be beneficial. Null mutations in which an allele is not expressed or absent may be amenable to gene therapy or alternatively after silencing a mutant allele, a normal gene could be supplied. In addition, overexpression of the normal collagen gene in cells expressing mutant collagen polypeptide chains potentially could lead to synthesis of a sufficient percentage of normal molecules to normalize clinical status. The authors currently are examining the possibility of developing gene therapy for treating a mouse model of human osteogenesis imperfecta (oim) using bone marrow stromal cells as vehicles for delivering normal collagen genes to bone. In the current study, the potential of gene therapy for treating osteogenesis imperfecta is discussed in the context of the complexity of the mutations in Type I collagen genes that lead to different osteogenesis imperfecta phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=0033774772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033774772&partnerID=8YFLogxK

U2 - 10.1097/00003086-200010001-00017

DO - 10.1097/00003086-200010001-00017

M3 - Article

C2 - 11039761

AN - SCOPUS:0033774772

SP - S126-S133

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 379 SUPPL.

ER -